Blog
RSS FeedPosted by Michael Wonder on 24 Apr 2018
Institute for Clinical and Economic Review to assess biologic treatments for asthma in upcoming assessment
24 April 2018 - Report will be subject of November Midwest CEPAC meeting; open input now being accepted until 10 ...
Posted by Michael Wonder on 16 Apr 2018
ICER's final report on emicizumab shows new treatment improves health while lowering costs for certain people with haemophilia A
16 April 2018 - Report also highlights need for future pricing of haemophilia treatments that allows for "shared savings" between innovators ...
Posted by Michael Wonder on 12 Apr 2018
ICER posts draft scoping document on therapies for prevention of hereditary angioedema attacks
12 April 2018 - Document open to public comment until 2 May 2018; report expected to review lanadelumab (Shire), and C1 ...
Posted by Michael Wonder on 12 Apr 2018
ICER releases draft evidence report on CGRP inhibitors for migraine prevention
11 April 2018 - Public comment period now open until 8 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 10 Apr 2018
ICER publishes guidance on improving the development and use of real world evidence for drug coverage and formulary decisions
10 April 2018 - The ICER, in collaboration with the Office of Health Economics, has released two new white papers to ...
Posted by Michael Wonder on 05 Apr 2018
ICER to assess medication-assisted therapy for treatment of opioid use disorder
5 April 2018 - Report will be subject of November New England CEPAC meeting; open Input now being accepted until 24 ...
Posted by Michael Wonder on 30 Mar 2018
ICER announces new program to make available draft executable economic models during drug assessment review process
30 March 2018 - Pilot program will allow more extensive evaluation of draft economic models used in ICER's reports. ...
Posted by Michael Wonder on 26 Mar 2018
ICER to assess therapies for hereditary angioedema in upcoming assessment
23 March 2018 - Review will be subject of October CTAF meeting; open input now being accepted until 9 April. ...
Posted by Michael Wonder on 24 Mar 2018
ICER final report on CAR-T therapies highlights need for systemwide changes to ensure affordability and access to innovative, one-time therapies
23 March 2018 - Policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...
Posted by Michael Wonder on 16 Mar 2018
ICER releases draft evidence report on CFTR modulator therapies for cystic fibrosis
15 March 2018 - Public comment period now open until 12 April; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018. ...
Posted by Michael Wonder on 13 Mar 2018
America’s “NICE”?
12 March 2018 - “The health of a democratic society may be measured by the quality of functions performed by ...
Posted by Michael Wonder on 13 Mar 2018
ICER requests public comment on two draft scoping documents: treatments for high-risk prostate cancer and amyloidosis
12 March 2018 - The ICER has posted two draft scoping documents outlining planned reviews of 1) three anti-androgen therapies ...
Posted by Michael Wonder on 12 Mar 2018
Regeneron and Sanofi announce plans to make Praluent (alirocumab) more accessible and affordable for patients with the greatest health risk and unmet need
10 March 2018 - For payers willing to reduce access barriers for high-risk patients, companies will offer net price within a ...